Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BLLN vs SHC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SHC Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

SHC Overall Winner 6-Pillar Tally: BLLN 2 – 4 SHC Matrix Metrics: BLLN 3 – 7 SHC

As of Nov 16, 2026, Sotera Health Company (SHC) is the stronger overall head-to-head candidate over BillionToOne, Inc. (BLLN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BLLN carries a Unified Composite Score of 45.8/100 (HOLD) at $96.31 (61.3x Forward P/E, 10.2% operating margin), whereas SHC carries 63.1/100 (BUY) at $16.25 (15.3x Forward P/E, 36.8% operating margin).

  • Growth vs. Quality Trade-Off: SHC earns the overall head-to-head edge with a stronger Unified Composite Score (63.1/100 BUY vs. BLLN 45.8/100 HOLD) and 0.95β · 44% Vol risk profile, whereas BLLN leads top-line expansion (+47.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: BLLN is currently in a Breakdown options structure phase (RSI 34.4); meanwhile SHC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BLLN vs SHC
BLLN US Equity
BillionToOne, Inc.
Services-Medical Laboratories
$96.31
-8.41% 1D
Market Cap $5.0B
TTM Revenue $437M
Forward P/E 61.3x
Beta / 30D Vol 1.44β · 42% Vol
Unified Composite Score
45.8 / 100 HOLD
Tech 27.0 Fund 53.0 Flow 71.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 34
RSI-14: 34.4 · SMA20: $109.99 · SMA50: $106.93
SHC NASDAQ Head-to-Head Winner
Sotera Health Company Common Stock
Services-Misc Health & Allied Services, Nec
$16.25
-2.17% 1D
Market Cap $4.7B
TTM Revenue $1.23B
Forward P/E 15.3x
Beta / 30D Vol 0.95β · 44% Vol
Unified Composite Score
63.1 / 100 BUY
Tech 60.0 Fund 56.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.9%), weak momentum, RSI 38
RSI-14: 38.1 · SMA20: $17.23 · SMA50: $17.91

6-Pillar Scorecard Institutional Category Breakdown (BLLN 2 – 4 SHC)

Columns: Metric · BLLN · SHC
1. Valuation Multiples SHC
Forward P/E 61.3x 15.3x
Trailing P/E 114.3x 27.7x
PEG Ratio N/M 1.68x
EV / Revenue 10.5x 3.9x
2. Growth & Scale BLLN
Revenue Growth (YoY) +47.2% +4.4%
Earnings Growth (YoY) +220.0% +17.6%
TTM Revenue (USD) $437M $1.23B
Market Cap $5.0B $4.7B
3. Profitability & Quality SHC
Gross Margin 71.4% 54.6%
Operating Margin 10.2% 36.8%
Net Profit Margin 10.5% 14.1%
Return on Equity (ROE) 13.2% 27.0%
4. Balance Sheet & Cash Flow SHC
Cash Generation (TTM) $34M $584M EBITDA
Cash Flow Margin 7.8% 47.5% EBITDA Mgn
Net Cash / Leverage $421M Net Cash $2.57 Book/Sh · 27.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SHC
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 113.8% (26th %ile) 56.1% (6th %ile)
Put/Call OI Skew 1.21x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BLLN
OpEx & R&D Intensity 61.2% of Rev ($267M) 17.8% of Rev ($219M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Diagnostics & Research Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BLLN (3) vs SHC (7)
Institutional Metric BLLN SHC Criterion Row Edge
Market Capitalization
Scale
$5.0B $4.7B Larger Scale BLLN
Trailing P/E Ratio
Valuation
114.3x 27.7x Lower Multiple SHC
Forward P/E Ratio
Valuation
61.3x 15.3x Lower Multiple SHC
Revenue Growth (YoY)
Growth
+47.2% +4.4% Higher Growth BLLN
Operating Margin (TTM)
Profitability
10.2% 36.8% Higher Margin SHC
Net Profit Margin
Profitability
10.5% 14.1% Higher Margin SHC
Return on Equity (ROE)
Capital Efficiency
13.2% 27.0% Higher ROE SHC
52-Week Range Position
Momentum
39% ($62–$150) 47% ($13–$20) Stronger Trend SHC
Beta / 30D Volatility
Risk Regime
1.44β · 42% Vol 0.95β · 44% Vol Lower Realized Risk BLLN
Unified Institutional Score
Composite Signal
45.8 / 100 (HOLD) 63.1 / 100 (BUY) Higher Composite SHC
Trailing 12M Revenue (USD)
Operating Scale
$437M $1.23B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
71.4% 54.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 10.5x EV/Rev 1.68x PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$34M ($421M Net Cash) $584M EBITDA ($2.57 Book/Sh · 27.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BLLN +7.33 pp
BLLN: -1.84% · SHC: -9.17%
3M Horizon BLLN +21.67 pp
BLLN: +9.46% · SHC: -12.21%
6M Horizon BLLN +5.97 pp
BLLN: +11.83% · SHC: +5.86%
1Y Horizon BLLN +6.05 pp
BLLN: +7.55% · SHC: +1.5%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BLLN vs SHC. Trailing 12-month operating profitability (BLLN 10.2% vs SHC 36.8%) and valuation multiples (BLLN 61.3x vs SHC 15.3x Forward P/E) are benchmarked directly in Pillar 4 below.

BLLN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$437M
Gross Margin71.4%
Op. Margin10.2%
ROE / Fwd P/E13.2% · 61.3x
SHC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.23B
Gross Margin54.6%
Op. Margin36.8%
ROE / Fwd P/E27.0% · 15.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BLLN BREAKDOWN
78d in phase · OBV DISTRIBUTION
Current IV 113.8%
IV Percentile 26th %ile
Put/Call OI Skew 1.21x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact BLLN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SHC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 56.1%
IV Percentile 6th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SHC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BLLN Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $5.0B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 61.2% of Rev ($267M)
90D Engineering Disclosures 0 Published
SHC Moat Profile High-Margin Pricing Power Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $4.7B market capitalization and 36.8% operating margin.
OpEx & R&D Reinvestment 17.8% of Rev ($219M)
90D Engineering Disclosures 0 Published

Investor FAQ BLLN vs SHC Key Questions & Quantitative Answers

As of Nov 16, 2026, Sotera Health Company (SHC) is the stronger overall head-to-head candidate over BillionToOne, Inc. (BLLN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BLLN carries a Unified Composite Score of 45.8/100 (HOLD) at $96.31 (61.3x Forward P/E, 10.2% operating margin), whereas SHC carries 63.1/100 (BUY) at $16.25 (15.3x Forward P/E, 36.8% operating margin). Growth vs. Quality Trade-Off: SHC earns the overall head-to-head edge with a stronger Unified Composite Score (63.1/100 BUY vs. BLLN 45.8/100 HOLD) and 0.95β · 44% Vol risk profile, whereas BLLN leads top-line expansion (+47.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: BLLN is currently in a Breakdown options structure phase (RSI 34.4); meanwhile SHC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BLLN leads the Growth & Scale pillar: BLLN posts +47.2% YoY revenue growth and +220.0% YoY earnings growth on $437M TTM revenue (71.4% gross margin, 10.2% operating margin), compared with SHC at +4.4% YoY revenue growth and +17.6% YoY earnings growth on $1.23B TTM revenue (54.6% gross margin, 36.8% operating margin). On trailing 12-month operating scale, BLLN generates $437M in USD-normalized revenue versus $1.23B for SHC. In operating R&D and SG&A reinvestment, BLLN deploys 61.2% of Rev ($267M) (0 90-day corporate R&D disclosures) versus 17.8% of Rev ($219M) (0 disclosures) for SHC.

SHC screens cheaper on headline valuation multiples. BLLN trades at 61.3x Forward P/E, 114.3x Trailing P/E, N/M PEG, and 10.5x EV/Revenue (7.8% FCF margin), whereas SHC trades at 15.3x Forward P/E, 27.7x Trailing P/E, 1.68x PEG, and 3.9x EV/Revenue (47.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BLLN (13.2% ROE) versus SHC (27.0% ROE) capital efficiency.

In options market volatility and institutional positioning, BLLN carries 113.8% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 1.21x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 42% Vol realized risk). By comparison, SHC carries 56.1% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.95β · 44% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.